Incyte and Merck expand clinical collaboration to include Phase III study investigating combination of Epacadostat with Keytruda as first-line treatment for advanced melanoma
The Phase 3 study, which is expected to begin in the first half of 2016, will be co-funded by Incyte and Merck. "We are very pleased to expand
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.